SYMBIOTEC PHARMALAB LTD SYMBIOTEC NSEPHARMA
Company Overview
Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and dermatology. The company provides contract manufacturing (CMO) and contract development and manufacturing (CDMO) services, particularly for fermentation-based APIs, and operates large-scale manufacturing facilities with dedicated research and development and quality control laboratories. Its product portfolio includes APIs outside the cortico-steroids and hormone categories, with several products under development. The company serves clients in the pharmaceutical industry, including organizations involved in pharmaceutical manufacturing, contract manufacturing, and research and development, as well as global pharmaceutical companies. The company was founded in 2002 and is based in Indore, India.
Why Investors Should Care
Net profit has compounded at 67.3% per year over the last five years.
Revenue has grown at a 16.8% CAGR over the past five years.
Operating margin of 21.2% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.34.
Recent Developments
- Mar 2026 Revenue of ₹869.15 Cr (+15.6% YoY); net profit ₹109.88 Cr.
- Trailing 12 Months Year-on-year growth — revenue +15.7%, earnings +13.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.8%, profit CAGR 67.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.78% |
| 1 Year: | 15.65% |
Compounded Profit Growth
| 5 Years: | 67.29% |
| 1 Year: | 13.53% |
Stock Price Performance
| 1 Year: | -1.77% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
P/E of 71.59 is above the sector median of 41.64 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.8% over 5 years.
- Profit CAGR of 67.3% over 5 years.
CONS
- Trading at a high P/E of 71.6.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SYMBIOTEC SYMBIOTEC PHARMALAB LTD NSEPHARMA | 1,078.25 | 71.59 | ₹6,928.42 Cr | 0.00% | 14.26% | 9.56% | 16.78% | 67.29% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Jun 2025 |
|---|---|
| Revenue | 199.85 Cr |
| Cost of Revenue | 83.42 Cr |
| Gross Profit | 116.44 Cr |
| Operating Expenses | 68.58 Cr |
| Operating Income | 47.85 Cr |
| EBITDA | 60.17 Cr |
| Interest Expense | 4.84 Cr |
| Pretax Income | 44.82 Cr |
| Tax Provision | 14.90 Cr |
| Net Income | 29.92 Cr |
| Diluted EPS | 4.66 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 545.78 Cr | 716.25 Cr | 751.55 Cr | 869.15 Cr |
| Cost of Revenue | 309.17 Cr | 321.01 Cr | 297.40 Cr | 315.46 Cr |
| Gross Profit | 236.60 Cr | 395.24 Cr | 454.15 Cr | 553.68 Cr |
| Operating Expenses | 192.41 Cr | 262.74 Cr | 295.41 Cr | 369.11 Cr |
| Operating Income | 44.20 Cr | 132.50 Cr | 158.74 Cr | 184.57 Cr |
| EBITDA | 72.17 Cr | 177.04 Cr | 206.11 Cr | 231.97 Cr |
| Interest Expense | 5.38 Cr | 7.24 Cr | 16.04 Cr | 25.33 Cr |
| Pretax Income | 38.27 Cr | 130.98 Cr | 146.97 Cr | 153.36 Cr |
| Tax Provision | 14.78 Cr | 30.93 Cr | 50.19 Cr | 43.46 Cr |
| Net Income | 23.47 Cr | 100.17 Cr | 96.78 Cr | 109.88 Cr |
| Diluted EPS | 3.65 | 15.59 | 15.06 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 989.99 Cr | 1,294.79 Cr | 1,579.65 Cr | 1,780.79 Cr |
| Current Assets | 400.17 Cr | 508.21 Cr | 492.86 Cr | 485.54 Cr |
| Cash & Equivalents | 4.55 Cr | 7.50 Cr | 26.39 Cr | 10.04 Cr |
| Inventory | 243.77 Cr | 335.79 Cr | 261.45 Cr | 236.88 Cr |
| Receivables | 111.95 Cr | 125.67 Cr | 175.65 Cr | 197.60 Cr |
| Total Liabilities | 368.55 Cr | 579.94 Cr | 764.95 Cr | 631.20 Cr |
| Current Liabilities | 228.07 Cr | 351.21 Cr | 472.60 Cr | 527.57 Cr |
| Long Term Debt | 112.00 Cr | 195.24 Cr | 253.01 Cr | 68.41 Cr |
| Total Debt | 219.96 Cr | 250.60 Cr | 544.44 Cr | 390.99 Cr |
| Total Equity | 621.53 Cr | 715.05 Cr | 814.89 Cr | 1,149.73 Cr |
| Shares Outstanding | 6.43 Cr | 6.43 Cr | 6.43 Cr | 6.43 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | 69.24 Cr | 187.50 Cr | 47.26 Cr | 174.59 Cr |
| Investing Cash Flow | -219.99 Cr | -206.41 Cr | -306.52 Cr | -226.93 Cr |
| Financing Cash Flow | 146.14 Cr | 21.85 Cr | 278.16 Cr | 35.99 Cr |
| Capital Expenditure | -224.39 Cr | -209.77 Cr | -308.12 Cr | -225.72 Cr |
| Free Cash Flow | -155.16 Cr | -22.27 Cr | -260.87 Cr | -51.13 Cr |
| Net Change in Cash | -4.61 Cr | 2.94 Cr | 18.89 Cr | -16.35 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 43.4% | 55.2% | 60.4% | 63.7% |
| Operating Margin % | 8.1% | 18.5% | 21.1% | 21.2% |
| Net Margin % | 4.3% | 14.0% | 12.9% | 12.6% |
| ROE % | 3.8% | 14.0% | 11.9% | 9.6% |
| ROCE % | 5.8% | 14.0% | 14.3% | 14.7% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SYMBIOTEC
SYMBIOTEC Share Price news: valuation and sector context - Univest
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQaU5GemRnLWxCWHpJd29TZzRQRDBFcFJnT2p6eEZ5NkJRRng0VlBnZGJPWDQtaEk3azFWclg5MGVtdDYyYV8xSXpoZWRPbVQyRmVaaXZVczktZW4yd25adTlGWkJnTUQtc0kxMW5sa0E3OXJmek1mVmlNVUN2WVV1YWJlY21UZ3c?oc=5" …
Symbiotec Pharmalab Shares Make Muted Debut. Lists With 1% Discount On BSE - NDTV Profit
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQS0h0RW9Rak13QWlNc05uSzNUVmNvLUhXajk2NDlXVm5GZmpXMGltNDVzTUVLVDRhYVpxQWI5ZTl4LU1fS0FRLVVjbFlKTTBLLWpkbEJIOUFHOVdTN1ZHQ2lJaEt5QXV2Qjc2dmR1SzIxdWxTbHhGM1VPZnNvenBmbHYyREpzQTJEc3dZb0…
Symbiotec Pharmalab shares end over 11% higher after flat debut - Rediff
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNUEt1eF9fakZmeWU1ZXZtUHppOUhqaWllaVhzUnNOS2ttY0VEZ2hPNzBBc3ROZy1QV2VNZmh1TC1QTDdCNkVDTlNrcUxFT2o4R0RVREhLeXBLQzFWVVhSWlhLWmg1VEJQZlFucm44enVnbFRYX1lhWTZra1BPR05iWHp6RlNwZVdweFJtU0…
Symbiotec Pharmalab shares make flat debut on exchanges; should you buy, sell or hold? - Moneycontrol.com
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxPUXJRQW5wZjljUmpEcHdiZlg2UktRNVI0cmpxTmd4UlhKUGVyRUtKV3RyLTJ2ZW8zNVU1RVBia3R5MFFTOU4yVGhDMzVyNjBzNllJdGo5XzVnOER3UzV1Z2xiVnl3Wmc4aFEyeDdEQlpaUEwxYVpGYU9nNkRGTllXYXZ3bnBneTNGX3dUWT…
Symbiotec Pharmalab IPO Listing Today: Shares Rise 11% After Flat NSE Debut; Check Price, Intraday High, Subscription and More - indiainfoline.com
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNOTFoYi1wRUdudDBxTjVhQlZISzNGbUZtSXg3YlRBYi1NNUtSN3VpWTE4VXpaLWhkSU9IQzB0aGNxNHRRMGtNVzFHMkhGcDExSjFfbm1VUTNDQTNjMUhicDVwa284UDRIV2k5TVhqQ1FhSWZ2VFI0YXBhOXRWZjNra0VZSEZjME4yTGVEQk…
Symbiotec Pharmalab vs Concord Biotech: Which Biotech Stock Is Better? - Equitymaster
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQeXdPZExoblBMcWRzdF9hM2JsaDBLYUJyMkNFblhONUFQX1B2dnc0VFREWDlBbVJ0UHhLbUdUOEJWNy1RUG51SFNPTDlDS3BsT1Y3N0VDTXV3UW13NG05c200SnBxZUNNVXVPYUwzaEwzRW52Y0NJSC1XZHlkREJqNHdQUDdUbUZfdUJRSl…
SYMBIOTEC — Frequently Asked Questions
What is the current share price of SYMBIOTEC PHARMALAB LTD (SYMBIOTEC)?
As of 2026-09-08 04:53 IST, SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) trades at ₹1,078.25 on NSE. Its 52-week range is ₹1,076.85 to ₹1,097.70.
What is the market capitalisation of SYMBIOTEC?
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of ₹6,928.42 Cr on NSE.
What is the P/E ratio of SYMBIOTEC?
SYMBIOTEC trades at a trailing price-to-earnings (P/E) ratio of 71.59. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 5.87.
What is the return on equity (ROE) of SYMBIOTEC?
SYMBIOTEC has a return on equity (ROE) of 9.56%. Its return on capital employed (ROCE) is 14.26%.
Is SYMBIOTEC a good stock to buy?
This page provides a data-driven analysis of SYMBIOTEC PHARMALAB LTD (SYMBIOTEC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.